Klarissa Jackson

Has grant

Assistant Professor

University of North Carolina at Chapel Hill

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Klarissa Jackson is an Assistant Professor at the University of North Carolina at Chapel Hill. Her research focuses on pharmacogenomics, specifically the metabolic pathways of various drugs and cannabinoids, as well as individual variations in drug metabolism. Recent articles include examinations of CYP3A and CYP2C8 enzymes in drug metabolism, the effects of sex and pregnancy on hepatic enzyme activity, and the pharmacokinetics of cannabidiol and its implications for precision medicine.

Recent Grants

Grant: Close

Interindividual Variability in Drug Metabolism in Ethnically Diverse Populations

Open Date: 2021-07-01

Close Date: 2026-06-30

Articles (17)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Klarissa Jackson

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (17)

Impact of sex and pregnancy on hepatic CYP3A4 expression and activity in a humanized mouse model

Impact of variation in CYP3A and CYP2C8 on tucatinib metabolic clearance in human liver microsomes

Interindividual variability in CYP3A‐mediated venetoclax metabolism in vitro and in vivo in patients with chronic lymphocytic leukemia

Advances and Challenges in Modeling Cannabidiol Pharmacokinetics and Hepatotoxicity

CBD and THC in Special Populations: Pharmacokinetics and Drug–Drug Interactions

Kinase Inhibitors FDA Approved 2018–2023: Drug Targets, Metabolic Pathways, and Drug-Induced Toxicities

A Review of CYP-Mediated Drug Interactions: Mechanisms and In Vitro Drug-Drug Interaction Assessment

Formation of CYP3A‐specific metabolites of ibrutinib in vitro is correlated with hepatic CYP3A activity and 4β‐hydroxycholesterol/cholesterol ratio

Cytosolic Enzymes Generate Cannabinoid Metabolites 7-Carboxycannabidiol and 11-Nor-9-carboxytetrahydrocannabinol

Novel Approaches to Characterize Individual Drug Metabolism and Advance Precision Medicine

Vaping additives cannabinoid oil and vitamin E acetate adhere to and damage the human airway epithelium

Bioactivation and reactivity research advances – 2021 year in review

Cytochromes P450 2C8 and 3A Catalyze the Metabolic Activation of the Tyrosine Kinase Inhibitor Masitinib

Interindividual Variability in Cytochrome P450 3A and 1A Activity Influences Sunitinib Metabolism and Bioactivation

Novel advances in biotransformation and bioactivation research – 2020 year in review

Cytochrome P450-Catalyzed Metabolism of Cannabidiol to the Active Metabolite 7-Hydroxy-Cannabidiol

Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors

Collaborators (8)

Craig Lee

Brahim Achour

Mehmet Kesimer

Grover P Miller

Herana Kamal Seneviratne

Nina Isoherranen

Jessica Beers

John Fallon

Make your next move.